Critical Care Ant-arrhythmic Drugs Global Market Strategies, Opportunity, Demand, Revenue Analysis And Forecast Outlook 2028

0
0

 

A new market study, titled “Critical Care Ant-arrhythmic Drugs Forecast 2021-2028” has been featured on Fortune Business Insights™.

 

***Get Latest Updated Market Research Report with Free Sample Report

Market Overview

Pune, India, 6th January 2021: The global critical care antiarrhythmic drugs market size is projected to reach USD 1,319.7 million by 2027, exhibiting a CAGR of 5.6% during the forecast period. Increasing prevalence of cardiovascular diseases (CVDs) around the world will be a major growth determinant for this market, highlights Fortune Business Insights™ in its report, titled “Critical Care Antiarrhythmic Drugs Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Beta Blockers, Calcium Channel Blockers, Sodium Channel Blockers, Potassium Channel Blockers, and Others),  By Disease Type (Supraventricular Arrhythmias, Ventricular Arrhythmias, and Others), and Regional Forecast, 2020-2027”. According to the World Health Organization (WHO), CVDs are the premier cause of global deaths, killing nearly 17.9 million people worldwide in 2016. Atrial fibrillation (AF) is the most frequent and the most commonly observed CVD. For example, the American Heart Association estimates that AF affects around 2.2 million people in the United States. More importantly, the incidence of AF is steadily rising. A study conducted by the Erasmus Medical Center in the Netherlands found that approximately 17.9 million people across Europe will be afflicted by AF in 2060. A similar epidemiological study conducted by researchers at the University of Arkansas revealed that in the US, between 6 million and 12 million people will suffer from AF by 2050. These projections indicate a steady rise in the demand for critical care antiarrhythmic drugs in the forthcoming decades as cardiac arrhythmia can turn fatal if not treated with effective medication in time.

Request for Free Sample Report PDF @ https://www.fortunebusinessinsights.com/enquiry/sample/critical-care-antiarrhythmic-drugs-market-104703

As per the report findings, the global market value stood at USD 796.8 million in 2019. The report also shares market information in the following manner:

  • Careful projections about the upcoming trends and prospects in the market;
  • Unmatched research into the regional dynamics of the market;
  • Granular analysis of the factors driving and restraining the market; and
  • Exhaustive profiling and examination of the key market players and their dominant strategies.

Driving Factor

Growing Importance of Heart Health amid COVID-19 to Boost the Market

The COVID-19 pandemic has reiterated the importance of maintaining heart health as patients suffering from heart-related comorbidities have been found to be at high risk of contracting the coronavirus. Early evidence from China’s Hubei and Wuhan provinces shows that 16.7% of the hospitalized patients and 44.4% of patients in intensive care units (ICUs) had cardiac arrhythmia. Another study conducted by researchers from the Perelman School of Medicine at the University of Pennsylvania in July 2020 revealed that the onset of the COVID-19 infection was associated with a high incidence of cardiac arrhythmias in patients. While the coronavirus is not solely responsible for the occurrence of cardiac abnormalities, the infection, in many cases, has worsened the preexisting conditions, leading to higher mortality rates among patients with chronic heart diseases. The coronavirus has, thus, heightened the adoption of critical care anti-arrhythmogenic drugs worldwide. The global market has, as a result, registered a CAGR of 12.9% in 2020.

Regional Insights

Robust Support to Medical Research to Accelerate Expansion of the North America Market

North America is poised to dominate the critical care antiarrhythmic drugs market share during the forecast period owing to the strengthening support to cutting-edge medical research in the US and Canada. Several government-funded organizations, academic institutions, and private entities are intensely engaged in undertaking clinical trials and developing novel drugs for complicated cardiac disorders. In 2019, the region’s market size stood at USD 359.2 million.

In terms of revenue and market share, Europe is expected to emerge as the second-largest region. The region’s market will be primarily driven by an increasing number of older persons suffering from cardiac conditions and favorable reimbursement policies. In Asia Pacific, rising awareness about atrial fibrillation and associated heart conditions will stoke regional market growth.

Competitive Landscape

Regulatory Backing to Novel Drug Formulations to Ensure Lasting Market Growth

Active support from regulatory bodies to novel formulations of drugs for antiarrhythmic treatment is fueling the critical care antiarrhythmic drugs market growth. Such backing from regulators is encouraging key players to innovate and scale up production, enabling them to cater to the widening demand for effective treatments for cardiac issues.

Industry Developments:

  • September 2020: Beximco Pharmaceuticals secured approval from the US Food and Drug Administration (FDA) for antiarrhythmic drug, Flecainide Acetate. The new drug has been formulated to treat abnormal heartbeats caused by conditions such as atrial fibrillation and tachycardia.
  • June 2020: ANI Pharmaceuticals introduced the Mexiletine Hydrochloride Capsules USP, the company’s sixth generic product launch of 2020. The capsules are indicated for the treatment of ventricular arrhythmias that are life-threatening.

Ask for Customization @ https://www.fortunebusinessinsights.com/enquiry/customization/critical-care-antiarrhythmic-drugs-market-104703

List of Key Companies Covered in the Market for Critical Care Antiarrhythmic Drugs:

  • Amomed Pharma GmbH (Vienna, Austria)
  • Mayne Pharma (Salisbury South, Australia)
  • Sanofi (Paris, France)
  • Mylan N.V. (Pennsylvania, U.S.)
  • Pfizer Inc. (New York, U.S.)
  • Upsher-Smith Laboratories, LLC. (Minnesota, U.S.)
  • GlaxoSmithKline plc (London, U.K.)
  • Baxter International Inc. (Deerfield, U.S.)
  • Novartis AG (Basel, Switzerland)

 

Table Of Content:

  1. Introduction

1.1. Research Scope                                                                                                                                   

1.2. Market Segmentation                                                                                                                     

1.3. Research Methodology                                                                                                                  

1.4. Definitions and Assumptions                                                                                                      

  1. Executive Summary
  2. Market Dynamics

3.1. Market Drivers                                                                                                                                      

3.2. Market Restraints                                                                                                                                              

3.3. Market Opportunities                                                                                                                      

  1. Key Insights

4.1. Epidemiology of Arrhythmias, For Key Countries/ Regions                                                       

4.2. Prevalence of Cardiovascular Disease – For Key Countries/ Regions                                    

4.3. Pipeline Analysis                                                                                                                                 

4.4. New Product Launches                                                                                                                   

4.5. Key Industry Developments – Partnerships, Mergers & Acquisitions                                    

4.6. Impact of COVID-19 Pandemic for Critical Care Antiarrhythmic Drugs Market             

  1. Global Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027

5.1. Key Findings / Summary                                                                                                                 

5.2. Market Analysis, Insights and Forecast – By Drug Class                                                               

5.2.1 Beta Blockers

5.2.2 Calcium Channel Blockers                                                                                                          

5.2.3 Sodium Channel Blockers                                                                                                           

5.2.4 Potassium Channel Blockers                                                                                    

5.2.5 Others                                                                                                                                    

5.3. Market Analysis, Insights and Forecast – By Disease Type                                                         

5.3.1 Supraventricular arrhythmias

5.3.2 Ventricular arrhythmias                                                                               

5.3.3 Others                                                                                                                                    

5.4. Market Analysis, Insights and Forecast – By Countries/ Sub regions                                    

5.4.1 North America                                                                                                                   

5.4.2 Europe                                                                                                                                   

5.4.3 Asia Pacific

5.4.4 Latin America                                                                                                                    

5.4.5 Middle East & Africa                                                                                                       

  1. North America Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027

6.1. Key Findings / Summary                                                                                                                 

6.2. Market Analysis – By Drug Class                                                                               

6.2.1 Beta Blockers                                                                                                     

6.2.2 Calcium Channel Blockers                                                                                                          

6.2.3 Sodium Channel Blockers                                                                                                           

6.2.4 Potassium Channel Blockers                                                                                    

6.2.5 Others                                                                                                                                   

6.3. Market Analysis, Insights and Forecast – By Disease Type                                                         

6.3.1 Supraventricular arrhythmias                                                                                   

6.3.2 Ventricular arrhythmias

6.3.3 Others                                                                                                                                    

6.4. Market Analysis, Insights and Forecast – By Country                                                                    

6.4.1. U.S.

6.4.2. Canada                                                                                                                                 

  1. Europe Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027

7.1. Key Findings / Summary                                                                                                                 

7.2. Market Analysis – By Drug Class                                                                                                

7.2.1 Beta Blockers

7.2.2 Calcium Channel Blockers                                                                                                                          

7.2.3 Sodium Channel Blockers

7.2.4 Potassium Channel Blockers                                                                     

7.2.5 Others                                                                                                                                    

7.3. Market Analysis, Insights and Forecast – By Disease Type                                                         

7.3.1 Supraventricular arrhythmias

7.3.2 Ventricular arrhythmias                                                                                               

7.3.3 Others                                                                                                                                    

7.4. Market Analysis, Insights and Forecast – By Countries/ Sub-region                                      

7.4.1. U.K.                                                                                                                                         

7.4.2. Germany

7.4.3. France                                                                                                                                    

7.4.4. Spain     

7.4.5. Italy        

7.4.6. Scandinavia       

7.4.7. Rest of Europe                  

  1. Asia Pacific Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027

8.1. Key Findings / Summary 

8.2. Market Analysis – By Drug Class

8.2.1 Beta Blockers     

8.2.2 Calcium Channel Blockers                          

8.2.3 Sodium Channel Blockers           

8.2.4 Potassium Channel Blockers                    

8.2.5 Others   

8.3. Market Analysis, Insights and Forecast – By Disease Type         

8.3.1 Supraventricular arrhythmias

8.3.2 Ventricular arrhythmias                                                                               

8.3.3 Others                                                                                                                                    

8.4. Market Analysis, Insights and Forecast – By Countries/ Sub-region                                      

8.4.1. Japan                                                                                                                                     

8.4.2. China

8.4.3. India                                                                                                                                       

8.4.4. Australia

8.4.5. Southeast Asia                                                                                                                

8.4.6. Rest of Asia Pacific                                                                                                        

  1. Latin America Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027

9.1. Key Findings / Summary 

9.2. Market Analysis – By Drug Class

9.2.1 Beta Blockers                     

9.2.2 Calcium Channel Blockers          

9.2.3 Sodium Channel Blockers                           

9.2.4 Potassium Channel Blockers    

9.2.5 Others                                                                                                                                   

9.3. Market Analysis, Insights and Forecast – By Disease Type

9.3.1 Supraventricular arrhythmias

9.3.2 Ventricular arrhythmias               

9.3.3 Others                    

9.4. Market Analysis, Insights and Forecast – By Countries/ Sub regions

9.4.1. Brazil                                     

9.4.2. Mexico                 

9.4.3. Rest of Latin America                                                                                                   

  1. Middle East & Africa Critical Care Antiarrhythmic Drugs Market Analysis, Insights and Forecast, 2016-2027

10.1. Key Findings / Summary                               

10.2. Market Analysis – By Drug Class             

10.2.1 Beta Blockers  

10.2.2 Calcium Channel Blockers       

10.2.3 Sodium Channel Blockers                        

10.2.4 Potassium Channel Blockers  

10.2.5 Others                 

10.3. Market Analysis, Insights and Forecast – By Disease Type                                                      

10.3.1 Supraventricular arrhythmias                                                                                

10.3.2 Ventricular arrhythmias

10.3.3 Others                                                                                                 

10.4. Market Analysis, Insights and Forecast – By Countries/ Sub regions                                  

10.4.1. South Africa                                                                                                                    

10.4.2. GCC

10.4.3. Rest of Middle East & Africa  

  1. Competitive Analysis

11.1. Key Industry Developments

11.2. Global Market Share Analysis (2019)

 11.3. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))       

11.3.1. Pfizer Inc.                           

11.3.2. GlaxoSmithKline plc  

11.3.3. Sanofi                  

11.3.4. Mylan N.V.       

11.3.5. Upsher-Smith Laboratories, LLC.       

11.3.6. Novartis AG     

11.3.7. Baxter                  

11.3.8. Mayne Pharma              

11.3.9. Amomed Pharma GmbH         

11.3.10. Other Prominent Players      

  1. Strategic Recommendations

Continued. . .

Related Article @

https://marketresearchreportsfbi.wordpress.com/2021/11/08/autotransfusion-devices-market-by-technology-share-size-segmentation-revenue-analysis-forecast-2028/ 

https://www.theexpresswire.com/pressrelease/Global-Surgical-Sutures-Market-Is-Projected-To-Grow-From-USD-341-Billion-In-2021-To-USD-512-Billion-In-2028-At-A-CAGR-Of-60-During-Forecast-Period-2021-28_14667642

NOTE: Our team is studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. We aim to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

LinkedIn: https://www.linkedin.com/company/fortune-business-insights

Facebook: https://www.facebook.com/FortuneBusinessInsightsPvtLtd

Twitter: https://twitter.com/FBInsightPvtLtd

Showing 0 results
Your Answer

Please first to submit.

Get involved

Register

As a member of this site you will be able to receive aggregates news relating only to those categories that are most relevant to you, submit job listings for FREE, post questions in the Q&A, and more.

Register Now

Feature your company

The Feature Your Company listing is your custom-made (by us) profile page that allows you to add any of the following content: text, videos, links, images. The page will also be listed on the Featured Company landing page. Over 560 unique aggregates users visit the site per day! Complete the enquiry form now to contact us.

Contact us

Jobs

Are you looking for an aggregate related job? Click here to see our jobs listing supplied by industry experts United Employment.

See Jobs

Advertise

Reach thousands of budget holders and decision makers by promoting your company on the longest established aggregate website in the US & Canada. Or advertise in our emails which are sent to opted-in subscribers according to their chosen categories. All advertising will display correctly on tablets and mobiles as this site is responsive.